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Introduction
Brain-derived neurotrophic factor (BDNF) plays a key role in synaptic plasticity and the survival and function of dopaminergic (DA) neurons within the ventral tegmental area-nucleus accumbens (VTA-NAc) pathway. In animal models, striatal in vivo infusions of BDNF locally augment spontaneous electrical activity of midbrain DA neurons (Shen et al., 1994) , enhance DA turnover (Altar et al., 1992) , and elevate DA-activity-dependent release (Goggi et al., 2002) . BDNF levels in DA cells in the VTANAc pathway also seem to be involved in the neuroadaptive changes occurring after intermittent brief episodes of social defeat stress, persistent chronic subordination (Berton et al., 2006; Krishnan et al., 2007; Miczek et al., 2011) , and responses to rewarding stimuli (Horger et al., 1999; Pierce and Bari, 2001; Lu et al., 2004) . BDNF injections into the VTA or the NAc enhance cocaine-induced locomotion (Pierce and Bari, 2001 ) and responses to cocaine cues for up to 30 d after the cessation of cocaine use (Lu et al., 2004) . In addition, BDNF heterozygote knock-out mice are also less responsive to cocaine's rewarding effects (Horger et al., 1999; Hall et al., 2003) .
In humans, mesolimbic activity and DA neurotransmission in the NAc are robustly engaged during the anticipation of a number of salient cues regardless of valence (Knutson et al., 2000; Scott et al., 2006; Scott et al., 2007b; McCabe et al., 2009; Spreckelmeyer et al., 2009 ). However, a potential role of BDNF on the processing of salient cues of different valences as it relates to DA neurotransmission has not been studied in humans. A common single-nucleotide polymorphism (SNP) in the BDNF human gene, Val 66 Met (rs6265), codes a substitution from valine (Val) to methionine (Met) at codon 66. It is postulated that Met substitution leads to inefficient trafficking of BDNF to secretory granules and reduced activity-dependent BDNF release (Egan et al., 2003; Chen et al., 2004; Chen et al., 2006) . This functional polymorphism has been associated with interindividual variations in cognitive function (Egan et al., 2003) , stress reactivity (Duman and Monteggia, 2006; Frielingsdorf et al., 2010; Colzato et al., 2011) , and reward processing (Gasic et al., 2009) .
Here, we studied the effect of the BDNF Val 66 Met functional polymorphism on anticipatory responses to monetary gains and losses during the fMRI monetary incentive delayed (MID) task and striatal DA neurotransmission during two challenges of opposite valence known to activate DA release, a stress-pain challenge (Scott et al., 2006) , and placebo administration with expectations of analgesia (Scott et al., 2008) using PET and the DA D 2/3 -selective receptor radiotracer [
11 C]-raclopride. Based on the animal literature and assuming effects regardless of valence, we initially hypothesized that, compared with Val homozygotes, decreased BDNF-dependent activity in Met carriers would result in lower functional responses during the anticipation of monetary gains and losses, lower baseline DA tone with a compensatory upregulation of D 2/3 receptors at baseline, and potentially lower DA release during both a painful stressor and placebo administration. The effects of BDNF Val 66 Met were expected within the VTA DA projections to the NAc, medial prefrontal cortex (mPFC), hippocampus (Hipp), and amygdala (AMY; Russo and Nestler, 2013) during the MID and in the NAc in the DA PET studies.
Materials and Methods

Subjects
Seventy-two subjects (34 females), age 20 -40 years (mean Ϯ SE, 26 Ϯ 0.5) were genotyped for BDNF Val 66 Met SNP (rs6265) and completed the MID task. Pain reports were collected (see "Experimental Design") in a subsample of 49 subjects (28 females, age 26.45 Ϯ 0.7 years) that participated in two PET scanning sessions during a pain-stress challenge with and without placebo administration as described previously (Scott et al., 2008) . Results on 20 of the 49 subjects in the present sample were part of a previous study examining the effects of placebo administration on -opioid and DA neurotransmission (Scott et al., 2008) . Main effects of placebo in the present sample replicated those in the previous study (Scott et al., 2008) and therefore are not reported here. BDNF Val 66 Met gene effects were not studied in this sample (Scott et al., 2008) due to insufficient power. In addition to completing physical and neurological examinations, study participants underwent screening using the nonpatient version of the Structured Clinical Interview for DSM-IV. Participants had no history of or current medical, neurological, or psychiatric illnesses, including substance abuse or dependence and had an alcohol intake of Ͻ5 drinks per week. Participants also had no first-degree family history of psychiatric illness. Women had regular menstrual cycles of 26 -32 d duration and had not used hormonal birth control for at least 1 year. We attempted to study women during the follicular phase using menstrual cycle diaries at screening and confirmatory progesterone levels at each PET scanning session ( progesterone levels of Յ1 ng/ml were confirmed in 23/28 women). Protocols were approved by the University of Michigan Investigational Review Board and the Radioactive Drug Research Committee and written informed consent was obtained from all subjects.
Genotyping BDNF Val
66 Met SNP (rs6265) was genotyped in all subjects using the Illumina Golden Gate Assay platform, the Addictions Array content of 130 genes (1350 SNPs), and 186 Ancestry Informative Markers (AIMs), which have been described previously (Hodgkinson et al., 2008) . Genotyping accuracy was confirmed by replicate genotyping of 10% of the total sample with a completion rate of Ͼ93% (mean 99.4%, median 100%) and replicates showed no errors at this loci. Because the sample was predominantly Caucasian (75%) and most of the non-Caucasians were African Americans (18%), the European and African ethnic factors (European and African AIM scores) were included as a continuous covariate in statistical analyses to account for the variability in allele frequencies across ethnicities.
MID and fMRI data acquisition and analysis
MID. Seventy-two participants completed a version of the MID (Knutson et al., 2000) . Each subject completed 2 runs consisting of 72 trials lasting 6 s each. A trial consisted of a cue representing a monetary value (small: Ϯ$0.20, medium: Ϯ$1.00, and large: Ϯ$5.00, null: $0), followed by an anticipation phase and a neutral target requiring button press with their right thumb. Subjects were then informed of their success on the preceding trial, in which they either gained or avoided losing the cued amount of money for monetary gain or loss trials, respectively. In the null trials, subjects experienced no monetary gain or loss but were still instructed to respond to the target. Subjects successfully hit the target an average of 45 Ϯ 24% of the gain trials and 44 Ϯ 24% of the loss response trials. Their average reaction time on gain trials was (165 Ϯ 41 ms) and on loss trials was (165 Ϯ 43 ms).
fMRI data acquisition. The blood oxygenation level-dependent (BOLD) signal was measured using a Signa 3-tesla scanner (General Electric) with standard RF coil using a T2* weighted pulse sequence (single-shot combined spiral in/out, gradient echo; repetition time ϭ 2 s; echo time ϭ 30 ms; flip-angle ϭ 90 deg; field-of-view ϭ 20 cm; 64-by-64 image matrix; slice thickness ϭ 4 mm; 29 oblique-axial slices; Glover and Law, 2001 ). This imaging protocol was selected to minimize signal loss due to magnetic susceptibility effects (Noll, 2002) . Field map images were collected to correct for B0 inhomogeneities (Noll et al., 1991) .
Data were reconstructed offline, slice-time corrected to the middle slice (Aguirre and D'Esposito, 1999) , and realigned to the first volume of each run to correct for intrascan movement using Statistical Parametric Mapping (SPM)-based algorithms (Friston et al., 1995) . Each session was visually inspected for artifacts and screened for excessive head movement (mean translational or rotational instantaneous head movement Ͼ0.55 mm). High resolution anatomical MRI studies were also acquired using an axial spoiled gradient recall T1-weighted sequence (echo time, 3.4 ms; repetition time, 10.5 ms; inversion time, 200 ms; flip angle, 25°; number of excitations, 1; using 124 contiguous images, 1.5 mm thickness).
To allow comparisons between individuals, a subject's MRI and functional images were coregistered and anatomically normalized by warping the anatomical T1-weighted image to a standard stereotactic space (Montreal Neurological Institute, MNI) using SPM8 (Wellcome Department of Cognitive Neurology, University College, London). Finally, functional images were smoothed with a Gaussian kernel (full width at half maximum 6 mm) to reduce residual interindividual variability. Smoothed functional images were band-pass filtered with a 128 s highpass filter to eliminate low-frequency signals.
Pain and placebo experimental design
Forty-nine subjects underwent two PET scans with [ 11 C]-raclopride. The experimental design, in the absence or presence of placebo, consisted of a painful condition starting at minute 45 and maintained for 20 min after radiotracer administration by a computer-controlled delivery system through the infusion of medication-grade hypertonic saline solution (5%) into the left masseter muscle. In this model of sustained deep somatic pain, the intensity of the painful stimulus is standardized across subjects (Zhang et al., 1993; Stohler and Kowalski, 1999) . Briefly, volunteers are asked to rate their pain intensity every 15 s from 0 (no pain) to 100 (most intense pain imaginable) using an electronic 0 -100 visual analog scale (VAS) placed in front of the scanner gantry during the pain condition. Initially, the subject-specific settings of the closed-loop system for maintaining muscle pain were established. This consisted of measuring each subject's response to a standard 0.15 ml bolus of 5% sodium chloride injected over a 15 s period as an impulsive input while recording the subject's pain intensity response every 15 s. A suitable infusion rate for the maintenance of pain over time was then estimated by comparing the subject's response to the mean response of 65 subjects of the same age range exposed to the same bolus. From that point on, the adaptive controller depended on feedback from subjects. The subject ratings of pain intensity every 15 s were fed back to the computer via an analog-digital board, which then changed the infusion rate to maintain pain at similar levels over time. The same individual infusion profiles generated during the pain challenges were used for the studies with placebo administration (Scott et al., 2008) .
During the placebo condition, subjects were given the following instructions before administration of the placebo: "We are studying the effect of a pain relief medication. This medication is thought to have analgesic effects through the activation of natural brain systems that suppress pain." The placebo condition consisted of the introduction of 1 ml of 0.9% isotonic saline into 1 of the intravenous ports every 4 min, with the volunteer being made aware that this was the case, starting 2 min before the pain challenges and lasting for 15 s each time. Subjects were aware that the study drug was to be administered because they were alerted by a computer-generated human voice recording, followed by a second-by-second count of the infusion timing (15 s). Based on our prior experience using a fully randomized design (Zubieta et al., 2005) , the placebo administration followed the pain challenge without placebo; this provided the subjects with a frame of reference for the expectation of analgesic effects. Each subject underwent four pain challenges, two of them with placebo administration, as described previously (Scott et al., 2008) , but only the results of two of the sets are reported here, those associated with [
11 C]-raclopride PET scanning. The order of each pair of pain and pain ϩ placebo studies was randomized. Pain and pain ϩ placebo studies were separated by 2 h (changes in nondisplaceable binding potential [BP ND ] do not persist in subsequent scans after the pain stressor; Scott et al., 2007a) .
Immediately after the pain and the pain ϩ placebo challenges, subjects completed the McGill Pain Questionnaire (MPQ; Melzack and Torgerson, 1971 ). This measure, together with a 0 -100 VAS pain intensity rating acquired every 15 s in the absence and presence of placebo, was used as the primary end point for the assessment of placebo responses. Levels of expectancy and effectiveness of placebo were rated before and after the placebo administration, respectively, with the following questions: for expectancy, "From 0 to 100 how effective do you think the treatment will be?"; for effectiveness, "From 0 to 100 how effective was the treatment?"
PET data acquisition and preprocessing
The two 90 min PET studies per subject were acquired (HR ϩ scanner; Siemens) in 3D mode (reconstructed full-width/half-maximum resolution, ϳ5.5 mm in plane and 5.0 mm axially), with the septa retracted and scatter correction. Participants were positioned in the PET scanner gantry and two intravenous (antecubital) lines were placed. A light forehead restraint was used to eliminate intrascan head movement. [
11 C]-raclopride was synthesized at high specific activity by the reaction of O-desmethyl raclopride with [
11 C]-methyl triflate. Then, 15.0 Ϯ 2.2 mCi was administered in each of the imaging procedures, with a mass of raclopride of 0.20 Ϯ 0.15 g/kg per image. These levels ensured that the compounds were administered in tracer quantities; that is, subpharmacological doses occupying Ͻ1% of the available receptors. Fifty percent of the [ 11 C]-raclopride dose was administered as a bolus, with the remainder delivered as a continuous infusion by a computer-controlled automated pump to more rapidly achieve steady-state tracer levels. For each study, 21 sets of dynamic scans were acquired with an increasing duration (4 30 s frames, 3 1 min frames, 2 2.5 min frames, 8 5 min frames, and 4 10 min frames). Images were reconstructed using iterative algorithms (brain mode; Fourier rebinning algorithm with ordered-subsets expectation maximization, four iterations, and 16 subsets; no smoothing) into a 128 ϫ 128 pixel matrix in a 28.8-cm-diameter field of view. Attenuation correction was performed through a 6 min transmission scan (Ge 68 source) obtained before the PET study and with iterative reconstruction of the blank/transmission data, followed by segmentation of the attenuation image. Small head motions during PET were corrected by an automated computer algorithm for each subject before analysis and the images were coregistered with the same software (Minoshima et al., 1993) . Time points were then decay corrected during reconstruction of the PET data. Image data were transformed on a voxel-by-voxel basis into two sets of parametric maps, a tracer transport measure (K 1 ratio) and a receptor-related measure (BP ND ), the latter using data obtained from 35-45 min (baseline) or 45-90 min ( pain stress Ϯ placebo) after tracer administration. This measure was obtained using the ratio of brain activity to activity in the cerebellum minus 1 (Carson et al., 1997; Watabe et al., 2000) . Using the bolus-continuous infusion protocol described in the experimental design, the slope of the Logan plot becomes linear ϳ5-7 min after tracer administration and is proportional to the receptor concentration divided by its affinity for the radiotracer as follows: (Innis et al., 2007) or receptor availability in vivo, B max is the receptor concentration, and K d is the receptor-ligand dissociation constant. The term f 2 refers to the concentration of free radiotracer in the extracellular fluid and is considered to represent a constant and very small value.
The K 1 and BP ND images for each experimental period and the MRIs acquired on the 3 tesla scanner described in fMRI data acquisition, above, were coregistered to each other and to the International Consortium for Brain Mapping stereotactic atlas orientation (Meyer et al., 1997) .
Three receptor-related measures were calculated: (1) DA D 2/3 BP ND during the pain challenge (45-90 min., scan 1); (2) DA D 2/3 BP ND during the pain ϩ placebo challenge (45-90 min., scan 2); and (3) baseline DA D 2/3 BP ND at equilibrium (35-45 min., scan 1). DA release during pain and placebo administration was assessed by calculating the difference between baseline (control) and pain conditions and between pain and pain ϩ placebo conditions. Reductions in the in vivo availability of DA receptors after an acute challenge are thought to reflect DA release and competition between radiotracer and endogenous ligand for the receptor sites (Narendran and Martinez, 2008) . A mask that included only regions with specific DA D 2/3 -receptor-binding potential (BP ND Ͼ 0.2) was used.
Statistical analyses
For the fMRI data, statistical analysis proceeded in two stages. At the first level, a general linear model was used to generate individual subjects' activation maps. The anticipation phase for each of the different monetary values was modeled separately as regressors of interest and was convolved with the hemodynamic response function. Six regressors modeling residual effects of head motion were included as nuisance parameters. The contrasts of interest generated with the model were: (1) anticipation of large gain versus neutral and (2) anticipation of large loss versus neutral. At the second level, contrast images were place into MNI space using the transformation matrix derived from the linear and nonlinear warping transformation matrices and random-effects analysis was used to determine group effects, resulting in statistical parametric (t or F ) maps. Statistical test were also applied to the two primary contrasts of interest, large gain minus neutral and large loss minus neutral conditions. A mask excluded the cerebellum and brainstem below the midbrain because these regions were not well represented. A voxel-by-voxel t test (fMRI) and mixed model of variance (PET) analysis were performed using SPM8 (Wellcome Department of Cognitive Neurology, University College, London) and MATLAB software (The MathWorks). To account for differences in sample sizes, we chose the unequal variance option in SPM for statistical analysis. Sex and European and African AIM factors were included as covariates. No global normalization was applied to the data.
The effects of BDNF Val 66 Met were hypothesized to take place within the VTA dopaminergic projections to the NAc, mPFC, Hipp, and AMY (Russo and Nestler, 2013) during the MID and within the NAc in the DA PET studies (because of the selective binding of [ 11 C]-raclopride in the striatum). The summary statistical maps in these regions were thresholded at p Ͻ 0.001 uncorrected for multiple comparisons (Friston, 1997), with a voxel extent Ͼ10 voxels; for other regions, p Ͻ 0.05 false discovery rate (FDR)/FWE correlation was considered significant. These data were extracted for quantification of regional changes in BOLD activation and BP ND , plotting, examination of potential outliers, and further statistical analyses using SPSS version 20.0 statistical software. ANCOVA models were performed on the psychophysical and extracted imaging data. Data are shown as the mean Ϯ 1 SD. Genotype was included as the between-subject factors and sex and European and African AIMs were included as the covariates of no interest. Statistical significance was considered at p Ͻ 0.05.
We used the SPSS 20.0 macro Mediate.sbs (http://afhayes.com/ spss-sas-and-mplus-macros-and-code.html) to estimate the path coefficients and the size of the indirect effect of the mediator model X (BDNF Val 66 Met) on Y (MPQ scores immediately after the pain challenge) through Z (BDNF Val 66 Met effect on NAc DA release during pain). ; Z-score ϭ 3.46) and right ventral striatum, although at a lower threshold (Fig. 2, Table 1 ). Baseline D 2/3 receptor BP ND in the ventral striatum was not associated with pain ratings or changes in pain ratings during placebo administration with expectation of analgesia.
Results
Genotyping
During the pain challenge, a voxelby-voxel analysis within the striatum showed a significant effect of BDNF Val 66 Met (n ϭ 49, Met 66 carriers Ͼ Val/ Val) on pain-induced D 2/3 system activation maps in the NAc bilaterally [left NAc: MNI peak coordinates Ϫ8, 6, Ϫ3; cluster size 38 mm 3 ; Z-score ϭ 3.58; in the right NAc: MNI peak coordinates 13, 11, Ϫ4; cluster size 25 mm 3 ; Z-score ϭ 3.23 (Fig. 3, Table 1) ]. Results remained significant after controlling for baseline DA BP ND in the NAc.
The magnitude of DA release in the NAc by the pain stressor was positively correlated with MPQ scores during the pain condition in the left NAc (MPQ total: r ϭ 0.41; p ϭ 0.003; MPQ sensory: r ϭ 0.39; p ϭ 0.006; MPQ pain effect: r ϭ 0.30; p ϭ 0.04; Fig. 3 ). We then conducted a mediation analysis to test whether DA release in the NAc mediates the effect of BDNF Val 66 Met on the subjective pain experience, measured by the MPQ. The mediation analysis confirmed the BDNF Val 66 Met effect on DA release in the NAc during the sustained pain challenge (coefficient ϭ Ϫ0.18, t ϭ Ϫ2.72, p ϭ 0.009) and the relationship between stress-induced DA release in the NAc and MPQ ratings (coefficient ϭ 23.8, t ϭ 3.2, p ϭ 0.002). The mean indirect effect (coefficient ϭ 0.13) from the bootstrap analysis was significant, with a 95% confidence interval excluding zero (Ϫ1.13 to Ϫ8.12) and the direct effect During placebo administration, the imaging data analysis showed a significant effect of BDNF Val 66 Met, in this case, Val/ValϾ Met 66 carriers (n ϭ 49), on placebo-induced D 2/3 system activation maps in the NAc bilaterally, where Met 66 carriers showed an overall deactivation of the DA system during placebo administration compared with Val carriers (n ϭ 49, Fig. 3, Table 1 ). Results remained significant after controlling for baseline DA BP ND in the NAc. Placeboinduced changes in DA neurotransmission in the NAc were not associated with changes in the subjective experience of pain during placebo administration.
Val
66 Met (rs6265) effect on pain ratings and placebo effectiveness At a psychophysical level, we found no significant, direct effect of BDNF Val 66 Met on pain ratings during or immediately after the pain challenge (n ϭ 49, average VAS scores acquired every 15 s during the challenge or MPQ scores). The volume of hypertonic saline to achieve average target pain ratings, a measure of pain sensitivity, was also not different between genotype or sex groups, nor was the ratio between VAS and volume infused. During the introduction of the placebo, we found no effect of BDNF Val 66 Met on psychophysical placebo responses.
Discussion
The Evidence from animal (Berridge and Robinson, 1998; Ikemoto and Panksepp, 1999) and human in vivo imaging studies have shown that DA neurons in the mesolimbic system, especially in the ventral striatum, increase their firing and DA release in response to reward (Wise, 2004; Schultz, 2006; Peciña et al., 2012) , but also to psychological (Pruessner et al., 2004; Montgomery et al., 2006; Soliman et al., 2008; Kobiella et al., 2010) , physical (Scott et al., 2006; Scott et al., 2008; Peciña et al., 2012) , or pharmacological stressors (Treadway et al., 2012) . BDNF plays a key role in the survival and function of DA neurons, including neurons in the VTA that project to the NAc. Animal studies have demonstrated that the rodent striatum is rich in BDNF protein supplied from afferent midbrain DA and corticostriatal glutamate neurons (Altar et al., 1992; Conner et al., 1997; Kolbeck et al., 1999) . Consistent with the neurotrophic role of BDNF in DA neurons in animal models, we observed a significant effect of BDNF Val 66 Met on DA receptor availability, in which BDNF Met 66 carriers showed greater baseline D 2/3 BP ND than Val/Val homozygotes. This is likely a consequence of an upregulation of this receptor sites in the presence of chronic lower DA tone, as would be expected by the lower BDNF function in this group.
Exogenous BDNF has been shown to promote the survival and differentiation of cultured DA neurons Spina et al., 1992) and is associated with an overall increase in tyrosine hydroxylase activity, DA release, DA transporter uptake capacity, and DA tissue content Knüsel and Hefti, 1991; Beck et al., 1993; Zhou et al., 1994; Blöchl and Sirrenberg, 1996; Hoover et al., 2007) . Consistent with this crucial role of BDNF in regulating DA release, we observed that the BDNF Val 66 Met polymorphism had effects on regional activation during the anticipation of monetary loss and pain-and placebo-induced DA release. However, BDNF Met 66 carriers, who had lower levels of BDNF and potentially lower activitydependent release of DA, had a selective increase in brain response to the anticipation of monetary losses (but not rewards) in the VTA-NAc-mPFC cortex and DA release in the NAc during the pain challenge (the latter correlating with subjective pain ratings), but an overall reduction in DA activity in the bilateral NAc during placebo administration compared with Val homozygotes. These results suggest a valence-selective effect of BDNF in regulating DA-mediated aversive stimuli. During the anticipation of monetary losses, greater BOLD responses were also observed in the Hipp in Met 66 carriers, a region involved in the regulation of DA neural activity via a Hipp-NAc-ventral pallidum-VTA pathway (Floresco et al., 2001) , and responses to aversive stimuli (Valenti et al., 2011) . Consistent with the data presented here, BDNF Met 66 has been robustly associated with impaired fear extinction learning and increased risk for anxiety disorders .
This pattern of greater BOLD responses to the anticipation of monetary loss, but no effect during the anticipation of monetary gain, as well as increases in stress-induced DA release and a blunted DA response during positive expectations (i.e., of pain relief) seems to point to a vulnerability phenotype. This vulnerability phenotype is in agreement with associations between low levels of BDNF and the development of depressive-like anhedonic responses in animal stress models (Duman and Monteggia, 2006) and persistent suppression of cocaine and saccharine reward after intermittent social stress in mice (Miczek et al., 2011) . These findings might also explain the neurobiology underlying the frequent comorbidity between mood and substance abuse disorders (Brady and Sinha, 2005) . On the contrary, animal models of stress have suggested that preventing BDNF signaling to the NAc may be a key molecular mechanism of stress resiliency (Berton et al., 2006; Krishnan et al., 2007) . Susceptibility to an avoidant phenotype was induced by upregulation of VTA neuronal activity, which resulted in increased BDNF signaling within the NAc (Berton et al., 2006) . Moreover, although Val/Val and Met/Met mice showed comparable baseline responses in forced swim and sucrose preference tests (Chen et al., 2006) , a differential phenotype became evident after chronic social defeat: whereas Val/Val mice demonstrated a significant reduction in social interaction after defeat, Met/Met mice displayed an unsusceptible phenotype (Krishnan et al., 2007) . As acknowledged by the investigators (Russo and Nestler, 2013) , an important caveat regarding that work is that most chronic stress paradigms in BDNF knock-out mice have relied solely on data acquired in males (Berton et al., 2006; Krishnan et al., 2007) . Data in female mice suggests that they may have increased stress vulnerability after chronic unpredictable stress (CUS; Autry et al., 2009) . In the present study, loss of BDNF in female mice was associated with increases in anxiety and depression-like behaviors after CUS compared with wild-type littermates, effects that were not observed in males. It has also been suggested that organizational differences in the development of reward-related neural circuits might predispose women to depression (Blehar, 2006) . Further studies would have to carefully consider a potential gene ϫ sex interaction modulating stress resiliency mechanisms in humans. The data presented here are not adequately powered to examine those interactions.
The present work provides initial evidence regarding the effect of BDNF Val 66 Met polymorphism modulating DA-mediated stress and reward responses in the human striatum. We identify a potential vulnerability phenotype in BDNF Met 66 carriers defined by: (1) greater BP ND in the NAc at baseline than Val homozygotes, suggesting chronic lower DA tone; (2) greater BOLD responses in the VTA-NAc-mPFC circuit during the anticipation of monetary losses, but not during gains; and (3) greater DA release in the NAc during a pain stressor, but a blunted DA response to the administration of a placebo with potential analgesic properties. Interindividual variability within the BDNF human gene therefore appears to be involved in the neuroplastic changes that follow responses to stress and might be involved in the vulnerability and recovery from stressful experiences, potentially affecting the pathophysiology and chronicity of stress related disorders.
